中药治疗多发性硬化疗效与安全性的系统评价与Meta分析
该系统评价纳入28项RCT共1971例多发性硬化患者,评估中药联合常规治疗的疗效与安全性。结果显示联合治疗在EDSS、年复发率、神经体征评分、MFIS及临床有效率方面均优于单用常规治疗,未报告严重不良事件,但纳入研究方法学质量欠佳。
要点
- 中药联合常规治疗可降低多发性硬化患者EDSS评分与年复发率。
- 联合治疗改善神经体征评分、疲劳评分及临床有效率。
- 未报告严重不良事件,但原始研究方法学质量欠佳。
核心结论
- 中药联合常规治疗对多发性硬化显示出有前景的疗效与安全性,但仍需高质量临床研究验证。
研究设计与样本
- 系统评价与Meta分析,检索8个数据库自建库至2025年7月,纳入28项RCT共1971例患者。
- 采用Cochrane手册评估偏倚风险,用RevMan 5.4.1与Stata 18.0进行定量合成。
- 已在PROSPERO注册,注册号CRD42024605890。
主要发现
- 中药联合常规治疗较单用常规治疗降低EDSS(MD=-0.65;95%CI:-0.96,-0.35;P<0.0001)。
- 联合治疗降低ARR(RR=0.48;95%CI:0.31,0.73;P=0.0007)。
- 联合治疗降低神经体征评分(MD=-2.96;95%CI:-4.52,-1.39;P=0.0002)。
- 联合治疗降低MFIS(MD=-8.55;95%CI:-10.20,-6.89;P<0.00001)。
- 联合治疗提高临床效果(RR=1.25;95%CI:1.19,1.32;P<0.00001),未报告严重不良事件。
临床怎么用
- 在常规治疗基础上可考虑联合中药以改善多发性硬化患者的残疾、复发与疲劳指标。
- 联合用药需关注安全性监测,原文未报告严重不良事件。
- 因原始研究方法学质量欠佳,临床决策应结合高质量证据与个体化评估。
局限性
- 纳入RCT的方法学质量相对欠佳。
- 原文指出需设计良好的临床研究提供高质量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple sclerosis (MS) is an incurable, chronic, disabling disease that primarily affects young adults. Chinese herbal medicine (CHM) is increasingly recognized as a major form of complementary and alternative medicine; however, there is a limited number of systematic analyses regarding its therapeutic effects on MS. AIM OF THE STUDY: This study aimed to evaluate whether CHM, when used alongside conventional treatment, offers additional therapeutic benefits for patients with MS, focusing on clinical efficacy and safety. MATERIALS AND METHODS: We searched eight databases from their inception until July 2025 to identify eligible randomized controlled trials (RCTs) involving CHM therapy for MS. Key outcomes assessed included the expanded disability status scale (EDSS), annual relapse rate (ARR), neurological signs scores, clinical symptoms scores, and modified fatigue impact scale (MFIS). The risk of bias was evaluated using the Cochrane Handbook for systematic reviews, while quantitative synthesis was performed with RevMan (version 5.4.1) and Stata (version 18.0) software. This review has been registered at the International Prospective Register of Systematic Reviews database (Registration No. CRD42024605890). RESULTS: This systematic review and meta-analysis included 28 RCTs involving a total of 1,971 participants. The combination of CHM and conventional therapy was superior to conventional therapy alone for individuals with MS. This was evidenced by a decrease in the EDSS (mean difference (MD) = -0.65; 95% confidence interval (CI): -0.96, -0.35; P < 0.0001; MD = -0.65, ARR (relative risk (RR) = 0.48; 95% CI: 0.31, 0.73; P = 0.0007), neurological signs scores (MD = -2.96; 95% CI: -4.52, -1.39; P = 0.0002), and MFIS (MD = -8.55; 95% CI: -10.20, -6.89; P < 0.00001). Additionally, there was an improvement in clinical effects (RR = 1.25; 95% CI: 1.19, 1.32; P < 0.00001). No serious adverse effect was reported. CONCLUSION: Although the methodological quality of the included RCTs was relatively suboptimal, CHM therapy combined with conventional therapy manifests a promising effectiveness and safety for managing MS. Therefore, well-designed clinical studies are necessary to provide high-quality evidence. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024605890, identifer CRD42024605890.
引用
- Guan X, Wu Y, Jia Q, et al. Efficacy and safety of Chinese herbal medicine for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025. PMID: 41059199. doi:10.3389/fphar.2025.1635833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。